New drug targets hard-to-treat KRAS cancers in early trial

NCT ID NCT07148128

Recruiting now Disease control Sponsor: Auricula Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC KRAS-MUTANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma carcinoma cholangiocarcinoma colorectal cancer colorectal neoplasm lung neoplasm non-small cell lung carcinoma ovarian serous adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC KRAS-MUTANT TUMOR ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN COLORECTAL CANCER ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN NON SMALL CELL LUNG CANCER ADVANCED OR METASTATIC KRAS-MUTANT TUMOR IN PANCREATIC ADENOCARCINOMA ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

NEXT Oncology Dallas
RECRUITING

Dallas, Texas, 75230, United States
Next Oncology, San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Oxford University Hospital
RECRUITING

Headington, Oxford, 0X3 9DU, United Kingdom
Princess Margareth Cancer Center
RECRUITING

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.